SynthesisBMC cancer2021
Trastuzumab administration during pregnancy: an update.
Synthesis in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Pregnancy-Associated Breast Cancer: A Trimester and Subtype Based Clinical Decision Framework for the Surgeon and Surgical Trainee.Annals of surgical oncology · 2026Review
- Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.Current treatment options in oncology · 2026Review
- Cancer During Pregnancy: Navigating Clinical and Research Challenges.Current oncology (Toronto, Ont.) · 2026Review
- Advances in the Treatment of Breast Cancer at Different Stages of Pregnancy.OncoTargets and therapy · 2026Review
- A Narrative Review of Evidence, Safety, and Clinical Considerations in Taxane Chemotherapy for Pregnancy-Associated Breast Cancer.Biomedicines · 2025Review
- Article
- Biology, care, and outcomes of gestational breast cancers: a review.Breast cancer research and treatment · 2025Review
- Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS database.Breast cancer research : BCR · 2025Article
- Chemo- and Radiotherapy of Gastrointestinal Tumors during Pregnancy.Visceral medicine · 2025Review
- Review
- Article
- Pregnancy and breast cancer in young women: current updates and future directions.Therapeutic advances in medical oncology · 2025Review
- Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns.JAMA network open · 2024Article
- Caring for Pregnant Patients with Cancer: A Framework for Ethical and Patient-Centred Care.Cancers · 2024Review
- Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns.JAMA network open · 2023Article
- Article
- Transplacental Passage and Fetal Effects of Antineoplastic Treatment during Pregnancy.Cancers · 2022Review
- Women at heart: Introducing gender cardio-oncology.Frontiers in cardiovascular medicine · 2022Review
- Current status of AYA-generation breast cancer: trends worldwide and in Japan.International journal of clinical oncology · 2022Review
- Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOver than one third (28-58%) of pregnancy-associated breast cancer (PABC) cases are characterized by positive epidermal growth factor receptor 2-positive (HER2) expression. Trastuzumab anti-HER2 monoclonal antibody is still the benchmark treatment of HER2-positive breast tumors. However, FDA has categorized Trastuzumab as a category D drug for pregnant patients with breast cancer. This systemic review aims to synthesize all currently available data of trastuzumab administration during pregnancy and provide an updated view of the effect of trastuzumab on fetal and maternal outcome.
methodsEligible articles were identified by a search of MEDLINE bibliographic database and ClinicalTrials.gov for the period up to 01/09/2020; The algorithm consisted of a predefined combination of the words "breast", "cancer", "trastuzumab" and "pregnancy". This study was performed in accordance with the PRISMA guidelines.
resultsA total of 28 eligible studies were identified (30 patients, 32 fetuses). In more than half of cases, trastuzumab was administered in the metastatic setting. The mean duration of trastuzumab administration during gestation was 15.7 weeks (SD: 10.8; median: 17.5; range: 1-32). Oligohydramnios or anhydramnios was the most common (58.1%) adverse event reported in all cases. There was a statistically significant decrease in oligohydramnios/anhydramnios incidence in patients receiving trastuzumab only during the first trimester (P = 0.026, Fisher's exact test). In 43.3% of cases a completely healthy neonate was born. 41.7% of fetuses exposed to trastuzumab during the second and/or third trimester were born completely healthy versus 75.0% of fetuses exposed exclusively in the first trimester. All mothers were alive at a median follow-up of 47.0 months (ranging between 9 and 100 months). Of note, there were three cases (10%) of cardiotoxicity and decreased ejection fraction during pregnancy.
conclusionsOverall, treatment with trastuzumab should be postponed until after delivery, otherwise pregnancy should be closely monitored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.